深圳市图微安创科技开发有限公司

T-Win Biotech is a clinical-stage biopharmaceutical company based in Shenzhen, China, focused on developing innovative small molecule drugs for metabolic and fibrotic diseases. The company utilizes a proprietary structure-based drug design (SBDD) platform to create highly selective therapies targeting nuclear receptors and G protein-coupled receptors. Its lead program, TWA1120, is a selective farnesoid X receptor (FXR) agonist currently in Phase 2 clinical development for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). T-Win Biotech's pipeline also features TWA1501, a thyroid hormone receptor beta (THR-beta) agonist, and other candidates aimed at treating hyperlipidemia and type 2 diabetes. The company aims to address significant unmet medical needs in the global metabolic disease market through its differentiated drug discovery approach.